Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6-months therapy: Correlation with androgen levels

Neuroendocrinology Letters

Volumn 27, Issue 6, 2006, Pages 763-767

  Kos Kudła, Beata ^a   Małecka Mikosz, Oliwia ^a   Foltyn, Wanda ^a   Ostrowska, Zofia ^a   Kudła, Marek ^a   Mazur, Bogdan ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Androgens; Ghrelin; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; DIANE; ESTRADIOL; GHRELIN; HYDROXYPROGESTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PROGESTERONE BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33846429212     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Balen A. Ovulation induction for polycystic ovary syndrome. Hum Fertil. 2003; 3: 106-11.
2. Calvo R, Asuncion M, Telleria D, Sancho J, San Millan S, Escobar-Morreale H. Screening for mutations in the steroidogenic acute regulatory protein and steroidogenic factor-1 genes, and in CYP11A and dosage-sensitive sex reversal-adrenal hypoplasia gene on the X chromosome, gene-1 (DAX-1), in hyprandrogenic hirsute women. J Clin Endocrinol Metab. 2001; 86: 1746-9.
3. Caminos J, Tena-Sempere M, Gaytǎn F, Sanchez-Criado J, Barreiro M, Nogueiras R, et al. Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology. 2003; 144: 1594-1602.
4. Chen H, Trumbauer M, Chen A, Weingarth D, Adams J, Frazier E, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004; 145: 2607-12.
5. Dunaif A. Genes and environment in the pathogenesis of PCOS. Gynecol Endocrinol. 2004; 18: 123.
6. Fica S, Gheorghisan A, Virtej I, Vladareanu R, Bunghez R. Prevalence of glucose metabolism abnormalities in polycystic ovary syndrome PCOS - insulin resistance and associated risks. Gynecol Endocrinol. 2004; 18: 308
7. Gambineri A, Pagotto U, Tschop M, Vicennati V, Manicardi E, Carcello A, et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2003; 26: 629-34.
8. Gaytan F, Barreiro M, Caminos J, Chopin L, Herington A, Morales C, et al. Expression of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in normal human testis and testicular tumors. J Clin Endocrinol Metab. 2004; 89: 404-9
9. Gaytan F, Barreiro M, Chopin L, Herington A, Morales C, Pinilla L, et al. Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in the cyclic human ovary. J Clin Endocrinol Metab. 2003; 88: 879-87
10. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, et al. Ev aluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006; 155(2): 337-45.
11. Katsuki A, Urakawa H, Gabazza EC, Murashima S, Nakatani K, Togashi K, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2004; 151: 573-7.
12. Legro R, Driscoll D, Strauss J, Fox J, Dunalf A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. U S A. 1998; 95: 14956-0.
13. Marzullo P, Verti B, Savia G, Walker G, Guzzaloni G, Tagliaferri M, et al. The relationship between active ghrelin levels and human obesity involves alterations in resting energy expenditure. J Clin Endocrinol Metab. 2004; 89: 936-9.
14. McLaughlin T, Abbasi F, Lamendola C, Frayo S, Cummings D. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab. 2004; 89: 1630-5.
15. Orio F, Lucidi P, Palomba S, Tauchmanova L, Cascella T, Russo T, et al. Circulating ghrelin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 942-5.
16. Pagotto U, Gambineri A, Vicennati V, Heiman M, Tschop M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab. 2002; 87: 5625-9.
17. Papotti M, Ghe C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000; 85: 3803-7.
18. Popovic V, Miljic D, Micic D, Damjanovic, Arvat E, Ghigo E, et al. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab. 2003; 88: 3450-3.
19. Poykko S, Kellokoski E, Horkko S, Kauma H, Kesaniemi A, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and prevalence of type 2 diabetes. Diabetes. 2003; 52: 2546-53.
20. Purnell J, Weigle D, Breen P, Cummings D. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol. Metab. 2003; 88: 5747-52.
21. Rosickǎ M, Kršek M, Matoulek M, Jarkovskǎ Z, Marek J, Justovǎ V, et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res. 2004; 52: 61-6.
22. Schofl C, Horn R, Schill T, Schlosser H, Muller M, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J. Clin Endocrinol Metab. 2002; 87: 4607-10.
23. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal M, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002: 87: 240-4.
24. Silfen M, Denburg M, Manibo A, Lobo R, Jaffe R, Ferin M, et al. Oberfield S. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescent. J Clin Endocrinol Metab. 2003; 88: 4682-8.
25. Staszewicz P, Kos-Kudła B, Strzelczyk J, Nasiek M. Metabolic consequences of policystic ovary syndrome. Diabetol Pol. 2003; 10: 346-52 (in polish).
26. Toshinai K, Date Y, Murakami N, Shimada M, Mondal M, Shimbara T, et al. Ghrelin - induced food intake is mediated via the orexin pathway. Endocrinology. 2003; 144: 1506-12.
27. Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez J, Gutiérrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12: 962-71.
28. Wood J, Nelson V, Ho C, Jansen E, Wang C, Urbanek M, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem. 200; 278: 26380-90.
29. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In:, Dunaif A, Givens JR, Haseltine FP, Merriam GR (Eds), (Series Ed: Hershman, SM), Current Issues in Endocrinology and Metabolism, 4, Blackwell Scientific Publications, Boston. 1992, chap.32.